secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001104659-23-068966
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa annual meeting elects three directors, ratifies auditor, approves say-on-pay
--------------------------------------------------------------------------------

- Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart elected as Class II directors with majority vote.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 (44.8M for, 23.6K against).
- Non-binding advisory vote on executive compensation approved (40.4M for, 1.3M against).
- All proposals passed; no annual meeting surprises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/0001104659-23-068966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/tm2317945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer